$3.59
6.76% today
Nasdaq, Apr 04, 09:20 pm CET
ISIN
US92539P1012
Symbol
VERV

Verve Therapeutics Inc Stock price

$3.85
-2.33 37.68% 1M
-0.88 18.54% 6M
-1.80 31.83% YTD
-4.87 55.86% 1Y
-19.33 83.41% 3Y
-28.08 87.95% 5Y
-28.08 87.95% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.07 1.66%
ISIN
US92539P1012
Symbol
VERV
Sector
Industry

Key metrics

Market capitalization $341.42m
Enterprise Value $-112.88m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.70
EV/Sales (TTM) EV/Sales -3.49
P/S ratio (TTM) P/S ratio 10.56
P/B ratio (TTM) P/B ratio 0.69
Revenue growth (TTM) Revenue growth 174.98%
Revenue (TTM) Revenue $32.33m
EBIT (operating result TTM) EBIT $-228.66m
Free Cash Flow (TTM) Free Cash Flow $-161.43m
Cash position $524.28m
EPS (TTM) EPS $-2.35
P/E forward negative
P/S forward 14.14
EV/Sales forward negative
Short interest 20.35%
Show more

Is Verve Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Verve Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Verve Therapeutics Inc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Verve Therapeutics Inc forecast:

Buy
80%
Hold
20%

Financial data from Verve Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
32 32
175% 175%
100%
- Direct Costs 6.75 6.75
36% 36%
21%
26 26
1,930% 1,930%
79%
- Selling and Administrative Expenses 45 45
55% 55%
139%
- Research and Development Expense 203 203
10% 10%
627%
-222 -222
4% 4%
-686%
- Depreciation and Amortization 6.75 6.75
36% 36%
21%
EBIT (Operating Income) EBIT -229 -229
2% 2%
-707%
Net Profit -199 -199
1% 1%
-615%

In millions USD.

Don't miss a Thing! We will send you all news about Verve Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verve Therapeutics Inc Stock News

Neutral
GlobeNewsWire
11 days ago
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for VERVE-102 for the treatment of patients living with heterozygous familial hypercholesterolemia (HeFH) and/...
Neutral
GlobeNewsWire
about one month ago
BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on February 28, 2025, the company granted equity awards to four new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment w...
Neutral
GlobeNewsWire
about one month ago
Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose escalation data in the second half of 2025
More Verve Therapeutics Inc News

Company Profile

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, and Burt A. Adelman in 2018 and is headquartered in Cambridge, MA.

Head office United States
CEO Sekar Kathiresan
Employees 274
Founded 2018
Website www.vervetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today